Want to see RADX full AI Analyst Report?
Top Page
Radiopharm Theranostics Limited Sponsored ADR
(NASDAQ:RADX)
Select Model
Select Model
Rating:43Neutral
Price Target:
$3.00
▼(-18.03% Downside)
Action:Reiterated
Date:07/29/26
Overall score is pressured primarily by weak financial performance (large ongoing losses and sustained cash burn) and bearish technical positioning (price below all key moving averages). Valuation provides limited support because negative earnings make P/E less informative and no dividend yield is available.
Positive Factors
Debt-free balance sheet
Radiopharm's zero-reported debt is a durable financial strength: conservative leverage lowers refinancing and interest risk, giving the company flexibility to prioritize R&D or partnerships. Over 2–6 months this buffers execution risk while clinical programs consume cash.
Negative Factors
Persistent cash burn
Consistent negative operating and free cash flow indicates ongoing reliance on external funding. Over 2–6 months this limits self-funding of trials, tightens runway assumptions, and forces recurring capital raises that can distract management and affect strategic optionality.
Read all positive and negative factors
Positive Factors
Negative Factors
Debt-free balance sheet
Radiopharm's zero-reported debt is a durable financial strength: conservative leverage lowers refinancing and interest risk, giving the company flexibility to prioritize R&D or partnerships. Over 2–6 months this buffers execution risk while clinical programs consume cash.
Read all positive factors
Radiopharm Theranostics Limited Sponsored ADR (RADX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$38.68M
Dividend YieldN/A
Average Volume (3M)287.79K
Price to Earnings (P/E)―
Beta (1Y)1.10
Revenue Growth110.08%
EPS Growth76.04%
CountryUS
Employees14
SectorGeneral
Sector StrengthN/A
IndustryBiotechnology
Share Statistics
EPS (TTM)-675.00
Shares Outstanding13,095,700
10 Day Avg. Volume45,935
30 Day Avg. Volume287,787
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)1.09
Price to Sales (P/S)13.46
P/FCF Ratio-1.33
Enterprise Value/Market Cap0.33
Enterprise Value/Revenue9.40
Enterprise Value/Gross Profit-10.41
Enterprise Value/Ebitda-0.44
Forecast
1Y Price Target
$16.00Price Target Upside337.16% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-4.29
Revenue Forecast (FY)$1.99M
Radiopharm Theranostics Limited Sponsored ADR Business Overview & Revenue Model
Company Description
Radiopharm Theranostics Limited, an Australian company established in Carlton in 2021, specializes in the research and development of cutting-edge radiopharmaceutical treatments. Their mission is to address critical gaps in healthcare by creating ...
How the Company Makes Money
null...
Radiopharm Theranostics Limited Sponsored ADR Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
62
Positive
Cash Flow
22
Negative
| Breakdown | TTM | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 1.36M | 3.63M | 299.23K | 292.36K | 8.83K |
| Gross Profit | -1.23M | 39.28K | 299.23K | 292.36K | 8.83K |
| EBITDA | -29.21M | -38.17M | -44.08M | -31.19M | -17.96M |
| Net Income | -26.47M | -38.34M | -47.95M | -34.61M | -30.34M |
Balance Sheet | |||||
| Total Assets | 91.08M | 86.48M | 72.04M | 74.95M | 83.38M |
| Cash, Cash Equivalents and Short-Term Investments | 34.48M | 29.12M | 18.58M | 11.70M | 26.98M |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 41.19M | 43.61M | 44.68M | 29.37M | 20.42M |
| Stockholders Equity | 51.73M | 44.79M | 28.12M | 44.38M | 62.96M |
Cash Flow | |||||
| Free Cash Flow | -22.26M | -36.65M | -22.98M | -24.73M | -38.25M |
| Operating Cash Flow | -22.26M | -36.65M | -22.98M | -23.20M | -9.92M |
| Investing Cash Flow | -5.21M | 1.77M | -320.00K | -1.53M | -28.37M |
| Financing Cash Flow | 32.82M | 45.43M | 30.20M | 9.22M | 65.11M |
Radiopharm Theranostics Limited Sponsored ADR Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
49 Neutral | $30.00M | -1.02 | -402.16% | ― | ― | ― | |
44 Neutral | $22.79M | -0.43 | -63.87% | ― | -100.00% | 21.30% | |
43 Neutral | $38.68M | -0.92 | -93.08% | ― | 110.08% | 76.04% | |
42 Neutral | $18.39M | -0.17 | 411.46% | ― | -51.03% | -35.20% | |
42 Neutral | $64.20M | -0.75 | -64.43% | ― | ― | 9.80% |
* General Sector Average
RADX
Radiopharm Theranostics Limited Sponsored ADR
3.15
-1.87
-37.25%
SER
Serina Therapeutics
2.00
-3.13
-61.03%
CELU
Celularity
0.64
-2.53
-79.91%
BRNS
Barinthus Biotherapeutics
0.56
-0.73
-56.82%
ACRV
Acrivon Therapeutics, Inc.
1.50
0.17
12.78%
TELO
Telomir Pharmaceuticals, Inc.
1.21
-0.62
-33.88%
Radiopharm Theranostics Limited Sponsored ADR Corporate Events
Radiopharm Theranostics Secures Multimillion-Dollar Financings to Advance Oncology Radiopharmaceutical Pipeline
Jul 28, 2026
On July 28, 2026, Radiopharm Theranostics closed a registered direct offering of 1,281,646 American Depositary Shares at US$3.16 per ADS, raising about US$4.1 million before fees from U.S. accredited institutional investors, alongside a concurrent...
Radiopharm Theranostics Lists 384 Million New Shares on ASX After ADS Placement
Jul 28, 2026
Radiopharm Theranostics Limited has applied to the Australian Securities Exchange for quotation of 384,493,800 new ordinary fully paid shares, with an issue date of July 28, 2026. The shares, priced at AUD 0.015 each, correspond to 1,281,646 Ameri...
Radiopharm Theranostics Launches Multimillion-Dollar U.S. ADS Offering and Australian Equity Raise to Fund Oncology Pipeline
Jul 27, 2026
Radiopharm Theranostics has arranged a US$4.1 million registered direct offering of 1,281,646 American Depositary Shares and a concurrent private placement of matching unregistered warrants to U.S. institutional investors, under a shelf registrati...
Radiopharm Theranostics Secures A$5.9 Million R&D Tax Refund to Fund Oncology Pipeline
Jul 6, 2026
On July 3, 2026, Radiopharm Theranostics announced it had received an A$5.89 million research and development tax refund from the Australian Government’s RD tax incentive program for the 2025 financial year. The refundable tax offset, which ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.